Cargando…

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined using a panel of strains with beta-lactamases cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lomovskaya, Olga, Sun, Dongxu, Rubio-Aparicio, Debora, Nelson, Kirk, Tsivkovski, Ruslan, Griffith, David C., Dudley, Michael N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655098/
https://www.ncbi.nlm.nih.gov/pubmed/28848018
http://dx.doi.org/10.1128/AAC.01443-17
_version_ 1783273467896922112
author Lomovskaya, Olga
Sun, Dongxu
Rubio-Aparicio, Debora
Nelson, Kirk
Tsivkovski, Ruslan
Griffith, David C.
Dudley, Michael N.
author_facet Lomovskaya, Olga
Sun, Dongxu
Rubio-Aparicio, Debora
Nelson, Kirk
Tsivkovski, Ruslan
Griffith, David C.
Dudley, Michael N.
author_sort Lomovskaya, Olga
collection PubMed
description Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined using a panel of strains with beta-lactamases cloned from various classes and a panel of Klebsiella pneumoniae carbapenemase 3 (KPC-3)-producing isogenic strains with various combinations of efflux and porin mutations. Vaborbactam is a potent inhibitor of class A carbapenemases, such as KPC, as well as an inhibitor of other class A (CTX-M, SHV, TEM) and class C (P99, MIR, FOX) beta-lactamases. Vaborbactam does not inhibit class D or class B carbapenemases. When combined with meropenem, vaborbactam had the highest potency compared to the potencies of vaborbactam in combination with other antibiotics against strains producing the KPC beta-lactamase. Consistent with broad-spectrum beta-lactamase inhibition, vaborbactam reduced the meropenem MICs for engineered isogenic strains of K. pneumoniae with increased meropenem MICs due to a combination of extended-spectrum beta-lactamase production, class C beta-lactamase production, and reduced permeability due to porin mutations. Vaborbactam crosses the outer membrane of K. pneumoniae using both OmpK35 and OmpK36, but OmpK36 is the preferred porin. Efflux by the multidrug resistance efflux pump AcrAB-TolC had a minimal impact on vaborbactam activity. Investigation of the vaborbactam concentration necessary for restoration of meropenem potency showed that vaborbactam at 8 μg/ml results in meropenem MICs of ≤2 μg/ml in the most resistant engineered strains containing multiple mutations. Vaborbactam is a highly active beta-lactamase inhibitor that restores the activity of meropenem and other beta-lactam antibiotics in beta-lactamase-producing bacteria, particularly KPC-producing carbapenem-resistant Enterobacteriaceae.
format Online
Article
Text
id pubmed-5655098
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-56550982017-10-30 Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae Lomovskaya, Olga Sun, Dongxu Rubio-Aparicio, Debora Nelson, Kirk Tsivkovski, Ruslan Griffith, David C. Dudley, Michael N. Antimicrob Agents Chemother Mechanisms of Resistance Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined using a panel of strains with beta-lactamases cloned from various classes and a panel of Klebsiella pneumoniae carbapenemase 3 (KPC-3)-producing isogenic strains with various combinations of efflux and porin mutations. Vaborbactam is a potent inhibitor of class A carbapenemases, such as KPC, as well as an inhibitor of other class A (CTX-M, SHV, TEM) and class C (P99, MIR, FOX) beta-lactamases. Vaborbactam does not inhibit class D or class B carbapenemases. When combined with meropenem, vaborbactam had the highest potency compared to the potencies of vaborbactam in combination with other antibiotics against strains producing the KPC beta-lactamase. Consistent with broad-spectrum beta-lactamase inhibition, vaborbactam reduced the meropenem MICs for engineered isogenic strains of K. pneumoniae with increased meropenem MICs due to a combination of extended-spectrum beta-lactamase production, class C beta-lactamase production, and reduced permeability due to porin mutations. Vaborbactam crosses the outer membrane of K. pneumoniae using both OmpK35 and OmpK36, but OmpK36 is the preferred porin. Efflux by the multidrug resistance efflux pump AcrAB-TolC had a minimal impact on vaborbactam activity. Investigation of the vaborbactam concentration necessary for restoration of meropenem potency showed that vaborbactam at 8 μg/ml results in meropenem MICs of ≤2 μg/ml in the most resistant engineered strains containing multiple mutations. Vaborbactam is a highly active beta-lactamase inhibitor that restores the activity of meropenem and other beta-lactam antibiotics in beta-lactamase-producing bacteria, particularly KPC-producing carbapenem-resistant Enterobacteriaceae. American Society for Microbiology 2017-10-24 /pmc/articles/PMC5655098/ /pubmed/28848018 http://dx.doi.org/10.1128/AAC.01443-17 Text en Copyright © 2017 Lomovskaya et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Mechanisms of Resistance
Lomovskaya, Olga
Sun, Dongxu
Rubio-Aparicio, Debora
Nelson, Kirk
Tsivkovski, Ruslan
Griffith, David C.
Dudley, Michael N.
Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
title Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
title_full Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
title_fullStr Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
title_full_unstemmed Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
title_short Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae
title_sort vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae
topic Mechanisms of Resistance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655098/
https://www.ncbi.nlm.nih.gov/pubmed/28848018
http://dx.doi.org/10.1128/AAC.01443-17
work_keys_str_mv AT lomovskayaolga vaborbactamspectrumofbetalactamaseinhibitionandimpactofresistancemechanismsonactivityinenterobacteriaceae
AT sundongxu vaborbactamspectrumofbetalactamaseinhibitionandimpactofresistancemechanismsonactivityinenterobacteriaceae
AT rubioapariciodebora vaborbactamspectrumofbetalactamaseinhibitionandimpactofresistancemechanismsonactivityinenterobacteriaceae
AT nelsonkirk vaborbactamspectrumofbetalactamaseinhibitionandimpactofresistancemechanismsonactivityinenterobacteriaceae
AT tsivkovskiruslan vaborbactamspectrumofbetalactamaseinhibitionandimpactofresistancemechanismsonactivityinenterobacteriaceae
AT griffithdavidc vaborbactamspectrumofbetalactamaseinhibitionandimpactofresistancemechanismsonactivityinenterobacteriaceae
AT dudleymichaeln vaborbactamspectrumofbetalactamaseinhibitionandimpactofresistancemechanismsonactivityinenterobacteriaceae